In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Scott Hammer on TWiV 52
• Meeting for molnupiravir EUA (FDA)
• SARS-CoV-2 reinfection associates with antibodies (Clinical Inf Dis)
• AFM surveillance in US (CDC)
• Monoclonal antibody treatment in high-risk patients (J Inf Dis)
• Letters read on TWiV 831
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]